Retraction
Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer
Paper Information
Record ID:
53981
Author(s):
Journal:
Publication Date:
March 29, 2024
Retraction Date:
June 03, 2024
(1.5 year years ago)
Subjects:
Institutions:
- Department of Obstetrics and Gynecologic, Division of Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center/James Cancer Hospital, USA
- Gynecologic Oncology Section, Women's Services and The Ochsner Cancer Institute, Ochsner Health, New Orleans, LA, USA
- Department of Pharmacy, The Ohio State University Wexner Medical Center, USA
Country:
🇺🇸 United StatesArticle Type:
Publisher:
Elsevier
Open Access:
Yes
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (2)
2
Total Citations1
Post-Retraction(50.0%)
0
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
1
Within 30 days
1
Within 1 year
0
After 2+ years
28
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Chemotherapie plus Dostarlimab ist beim Endometriumkarzinom kosteneffizient
Judith Lorenz
Geburtshilfe und Frauenheilkunde
Published: Jul 2024
28 days after retraction
Quick Stats
Total Citations:
2
Years Since Retraction:
1.5 year
Open Access:
Yes
Last Checked:
Jul 24, 2025